Mangone, A.
Favero, V.
Prete, A.
Elhassan, Y. S.
Asia, M.
Hardy, R.
Mantovani, G.
Chiodini, I.
Ronchi, C. L. http://orcid.org/0000-0001-5020-2071
Funding for this research was provided by:
Birmingham Biomedical Research Centre (NIHR203326, BRC-1215-20009)
Article History
Received: 19 January 2024
Accepted: 26 June 2024
First Online: 4 July 2024
Declarations
:
: I.C. has served on the advisory boards of HRA Pharma and Corcept Therapeutics. C.R. has received a research grant from HRA Pharma Rare Disease. All other authors have nothing to disclose in relation to this work.
: This study has been conducted in accordance with the Declaration of Helsinki. Institutional review board approval for retrospective data review from patients undergoing routine clinical care was obtained from the University Hospital Birmingham NHS Foundation Trust (reference CARMS-18109).
: For this type of study, no informed consent is requested.